Lockheed Martin Corporation LMT
Composite 50/100; the shares have moved about 30% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 36/100 — a moderate mark against it.
Income ranks 68/100 — a moderate point in its favour. Quality ranks 64/100 — a moderate point in its favour.
Balance-sheet strength ranks 36/100 — a moderate mark against it. Momentum ranks 44/100 — a slight mark against it. Growth ranks 47/100 — a slight mark against it.
What the company does Lockheed Martin designs and manufactures advanced aerospace and defense systems across four segments: Aeronautics, Missiles and Fire Control, Rotary and Mission Systems, and Space. Its portfolio includes combat aircraft, missile defense systems, satellites, and cyber solutions for military and commercial markets globally.
Key financials Profitability is strong with ROE 89% and net margin 8.2%, though EPS growth is negative at -3%. Margins show gross 11.8%, operating 12.0%. Leverage is high with Debt/Equity 2.34 and Net debt/EBITDA 1.73; liquidity is modest with current ratio 1.19. Dividend yield is 2.5% with a 50.9% payout ratio.
Stock health Quality score 63.7 is above average, but growth (45.5), strength (35.9), and momentum (45.3) are weak. Revenue growth is positive at 5.7%, while trailing P/E is 20.80 and forward P/E is 18.62. RSI(14) is 40.30, indicating neutral momentum.
Price vs fair value The stock trades at a discount of 16.20% versus the analyst mean target of 632.95. - Recent Pentagon deal to triple Patriot missile production supports demand visibility (2026-09-02). - Poland’s defense buildup may redirect spending away from Lockheed toward regional suppliers (2026-09-01). - Analyst blog highlights Lockheed alongside peers, suggesting balanced sector sentiment (2026-09-01). - YTD gain of 12.6% reflects positive execution despite broader market volatility (2026-09-02).
Looking forward Forward PEG of 1.59 and EV/EBITDA of 14.42 suggest moderate valuation relative to growth. With high ROE and strong backlog visibility, execution on large contracts will be key to sustaining margins and closing the valuation gap.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.